Endotoxin is an important pathogenic trigger for
sepsis. The
polymyxin B-immobilized
endotoxin removal
hemoperfusion cartridge, Toraymyxin (hereafter PMX), has been shown to remove
endotoxin in preclinical and open-label clinical studies. In a multicenter, open-label, pilot, randomized, controlled study conducted in the intensive care unit in six academic medical centers in Europe, 36 postsurgical patients with
severe sepsis or
septic shock secondary to
intra-abdominal infection were randomized to PMX treatment of 2 h (n = 17) or standard
therapy (n = 19). PMX was well tolerated and showed no significant side effects. There were no statistically significant differences in the change in
endotoxin levels from baseline to 6 to 8 h
after treatment or to 24 h
after treatment between the two groups. There was also no significant difference in the change in
interleukin (IL)-6 levels from baseline to 6 to 8 h
after treatment or to 24 h
after treatment between the two groups. Patients treated with PMX demonstrated significant increases in cardiac index (CI; P = 0.012 and 0.032 at days 1 and 2, respectively), left ventricular
stroke work index (LVSWI, P = 0.015 at day 2), and
oxygen delivery index (DO2I, P = 0.007 at day 2) compared with the controls. The need for
continuous renal replacement therapy (CRRT) after study entry was reduced in the PMX group (P = 0.043). There was no significant difference between the groups in organ dysfunction as assessed by the Sequential Organ Failure Assessment (SOFA) scores from day 0 (baseline) to day 6. Treatment using the PMX cartridge is safe and may improve cardiac and renal dysfunction due to
sepsis or
septic shock. Further studies are needed to prove this effectiveness.